Efficacy and safety of izokibep, a novel IL-17A inhibitor, in moderate-to-severe hidradenitis suppurativa: Week 12 results from a randomized, double-blind, placebo-controlled, multicenter, phase 3 study

izokibep (ABY-035) - ACELYRIN

https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eadv/abstracts_congress_2024/49469.pdf

Kim A. Papp*1; 2; Falk G. Bechara3; Martina L Porter4; Seth Forman5; Howard Sofen6; Jacek Szepietowski7; Benjamin D. Ehst8; Antonio Martorell Calatayud9; Anne M. Stevens10; 11; Brian Wiens10; Katya Cherny10; Shephard Mpofu10; Alexa B. Kimball4

Sep 18, 2024